HUYABIO INTL. REPORTS POSITIVE PHASE 2A TRIAL RESULTS FOR HBI-3000 IN ACUTE ATRIAL FIBRILLATION

HUYABIO International has introduced new insights into HBI-3000, an innovative investigational drug, emphasizing its potential in treating atrial fibrillation (AF) with enhanced safety and efficacy. This drug, characterized by its bioinspired antiarrhythmic properties, will be prominently featured at the Heart Rhythm Annual Meeting held from April 24 to April 27 in San Diego, California.

Dr. Mireille Gillings, the President, CEO, and Executive Chair of HUYABIO, articulated the pressing need for advanced treatment options for AF, highlighting that HBI-3000 could transform rhythm control therapies. Current antiarrhythmic drugs, while effective, pose significant risks, including fatal arrhythmias and sudden death. HBI-3000, with sulcardine as its active ingredient, aims to mitigate these risks while ensuring necessary therapeutic efficacy. This new formulation is designed to lower the chances of life-threatening arrhythmias, addressing a critical gap in current treatment regimens.

Findings from the HBI-3000-402 trial will be presented at the meeting, where the drug was administered as an intravenous infusion, showing promising results. Participants with acute-onset AF experienced notable therapeutic benefits, and the medication was well-tolerated. Dr. Denis Roy, the lead investigator of the Phase 2 trial, emphasized the promising outcomes, asserting the need for a more effective and safer antiarrhythmic drug for quickly managing AF.

Atrial fibrillation is a prevalent and serious cardiovascular disorder in the United States, especially with an aging population. Many antiarrhythmic drugs available today have severe side effects, including proarrhythmia and QT prolongation, leading to an urgent call for solutions that are both safe and effective.

The poster session titled "Safety and Efficacy Of HBI-3000, An Investigational Multichannel Blocker for Patients with Non-Permanent Atrial Fibrillation: Initial Clinical Findings" is scheduled for presentation on April 27, 2025. Dr. Denis Roy will lead this session, focusing on the effects of a single 30-minute IV infusion of HBI-3000 in converting AF to sinus rhythm in hospital environments.

HUYABIO International is recognized as a leader in accelerating the development of biopharmaceutical products from China, facilitating more cost-effective and lower-risk drug development in the global marketplace. By collaborating with biopharmaceutical, academic, and commercial entities, HUYABIO has curated a vast compound portfolio spanning all therapeutic areas. With operational bases in the US, Japan, Europe, and numerous strategic locations across China, HUYABIO has established itself as a preferred partner for global product development and value maximization.

Authors contributing to the study include Denis Roy from the Montreal Heart Institute, Suzanne Romano, Jay W. Mason from the University of Utah, Monica Wynn, Charles Pollack from the University of Mississippi Medical Center, Gary Elliot from Galenic Strategies, Mireille Gillings, and Jerome B. Riebman, all affiliated with HUYABIO International. This collaborative effort underscores the multi-faceted expertise driving the development of HBI-3000 and its potential to revolutionize AF treatment.